Related references
Note: Only part of the references are listed.Nrf2/P-glycoprotein axis is associated with clinicopathological characteristics in colorectal cancer
Mohammad Reza Sadeghi et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Nrf2 overexpression is associated with P-glycoprotein upregulation in gastric cancer
Farhad Jeddi et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
The role of Her2-Nrf2 axis in induction of oxaliplatin resistance in colon cancer cells
Abbas Pirpour Tazehkand et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Results and challenges of immune checkpoint inhibitors in colorectal cancer
Sheik Emambux et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Evolving notions on immune response in colorectal cancer and their implications for biomarker development
Fabio Grizzi et al.
INFLAMMATION RESEARCH (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy
Bo Zhu et al.
ONCOGENE (2018)
Strategy to targeting the immune resistance and novel therapy in colorectal cancer
Wang Gang et al.
CANCER MEDICINE (2018)
PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer
Magalie Dosset et al.
ONCOIMMUNOLOGY (2018)
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study
Nicolas Delanoy et al.
Lancet Haematology (2018)
Immunotherapy in colorectal cancer: for the select few or all?
Sukeshi Patel Arora et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
Global patterns and trends in colorectal cancer incidence and mortality
Melina Arnold et al.
GUT (2017)
Immunotherapy for colorectal cancer: where are we heading?
Debora Basile et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy
Cristina Maccalli et al.
IMMUNOLOGICAL INVESTIGATIONS (2017)
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer A Randomized Clinical Trial
Alan P. Venook et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Synthesis and characterization of folate decorated albumin bio-conjugate nanoparticles loaded with a synthetic curcumin difluorinated analogue
Kaustubh A. Gawde et al.
JOURNAL OF COLLOID AND INTERFACE SCIENCE (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer
Sanja Stevanovic et al.
SCIENCE (2017)
Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
Krzysztof M. Zak et al.
STRUCTURE (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
Peng-Fei Wang et al.
FRONTIERS IN PHARMACOLOGY (2017)
Immunoscore in mismatch repair-proficient and -deficient colon cancer
Erkki-Ville Wirta et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2017)
Contradictory roles of Nrf2/Keap1 signaling pathway in cancer prevention/promotion and chemoresistance
Farhad Jeddi et al.
DNA REPAIR (2017)
Innovative methods for the identification of predictive biomarker signatures in oncology: Application to bevacizumab
Paul Delmar et al.
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS (2017)
PD-1/PD-L1 as a prognostic factor in leukemia
Hadi Rezaeeyan et al.
JOURNAL OF HEMATOPATHOLOGY (2017)
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Rodrigo Dienstmann et al.
NATURE REVIEWS CANCER (2017)
Extent and Location of Tumor-Infiltrating Lymphocytes in Microsatellite-Stable Colon Cancer Predict Outcome to Adjuvant Active Specific Immunotherapy
Annelies W. Turksma et al.
CLINICAL CANCER RESEARCH (2016)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study
Kuo-Hsing Chen et al.
BMC CANCER (2016)
Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy
Etienne Becht et al.
CLINICAL CANCER RESEARCH (2016)
The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy
James W. T. Toh et al.
CLINICAL COLORECTAL CANCER (2016)
High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine
Zoran Gatalica et al.
FAMILIAL CANCER (2016)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J. R. Ebert et al.
IMMUNITY (2016)
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt et al.
IMMUNITY (2016)
PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers.
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Additional Support for the Introduction of Immune Cell Quantification in Colorectal Cancer Classification
Robert L. Ferris et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Tumor-Infiltrating Lymphocytes, Crohn's-Like Lymphoid Reaction, and Survival From Colorectal Cancer
Laura S. Rozek et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade Enhanced Cancer Photodynamic Immunotherapy
Dangge Wang et al.
NANO LETTERS (2016)
Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism
Wei Yang et al.
NATURE (2016)
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
Olivier De Henau et al.
NATURE (2016)
PI3Kγ is a molecular switch that controls immune suppression
Megan M. Kaneda et al.
NATURE (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant
Roberta Pascolutti et al.
STRUCTURE (2016)
Learning from PD-1 Resistance: New Combination Strategies
Xia Bu et al.
TRENDS IN MOLECULAR MEDICINE (2016)
Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer
Pietro Parcesepe et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2016)
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
Marios Giannakis et al.
CELL REPORTS (2016)
Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer
Cong-Min Zhang et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2016)
TGFβ-dependent expression of PD-1 and PD-L1 controls CD8+ T cell anergy in transplant tolerance
Marije Baas et al.
ELIFE (2016)
Additional Support for the Introduction of Immune Cell Quantification in Colorectal Cancer Classification
Robert L. Ferris et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Tumor-Infiltrating Lymphocytes, Crohn's-Like Lymphoid Reaction, and Survival From Colorectal Cancer
Laura S. Rozek et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Mreg Activity in Tumor Response to Photodynamic Therapy and Photodynamic Therapy-Generated Cancer Vaccines
Mladen Korbelik et al.
CANCERS (2016)
Patterns of metastasis in colon and rectal cancer
Matias Riihimaki et al.
SCIENTIFIC REPORTS (2016)
Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
Lorenzo Galluzzi et al.
CANCER CELL (2015)
Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice
Manabu Takamatsu et al.
CANCER SCIENCE (2015)
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Santiago Zelenay et al.
CELL (2015)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
PD-1/PD-L1 inhibitors
Joel Sunshine et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
The consensus molecular subtypes of colorectal cancer
Justin Guinney et al.
NATURE MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
Krzysztof M. Zak et al.
STRUCTURE (2015)
Clinical Implications of Microsatellite Instability in T1 Colorectal Cancer
Jeonghyun Kang et al.
YONSEI MEDICAL JOURNAL (2015)
The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy
Yanping Xiao et al.
CANCER DISCOVERY (2015)
Apoptosis of tumor infiltrating effector TIM-3+CD8+T cells in colon cancer
Chiao-Wen Kang et al.
SCIENTIFIC REPORTS (2015)
Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy
Mihaela Angelova et al.
GENOME BIOLOGY (2015)
Melanoma Induces, and Adenosine Suppresses, CXCR3-Cognate Chemokine Production and T-cell Infiltration of Lungs Bearing Metastatic-like Disease
Eleanor Clancy-Thompson et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
George K. Philips et al.
INTERNATIONAL IMMUNOLOGY (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
Immunological hallmarks of stromal cells in the tumour microenvironment
Shannon J. Turley et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Autophagy promotes resistance to photodynamic therapy-induced apoptosis selectively in colorectal cancer stem-like cells
Ming-Feng Wei et al.
AUTOPHAGY (2014)
Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Derek A. Wainwright et al.
CLINICAL CANCER RESEARCH (2014)
Immunodominance and Functional Alterations of Tumor-Associated Antigen-Specific CD8+ T-Cell Responses in Hepatocellular Carcinoma
Tobias Flecken et al.
HEPATOLOGY (2014)
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
Liufu Deng et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
The effect of immune microenvironment on the progression and prognosis of colorectal cancer
Jinxiang Chen et al.
MEDICAL ONCOLOGY (2014)
Colorectal cancer and immunity: what we know and perspectives
Simon Pernot et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
PD-L1 expression and tumor-infiltrating lymphocytes Revisiting the antitumor immune response potential in breast cancer
Kurt A. Schalper
ONCOIMMUNOLOGY (2014)
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
Thomas F. Gajewski et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Gabriela Bindea et al.
IMMUNITY (2013)
Molecular Pathways Involved in Colorectal Cancer: Implications for Disease Behavior and Prevention
Dora Colussi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Immune cells: plastic players along colorectal cancer progression
Giuseppe Di Caro et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2013)
Soluble CD80 Restores T Cell Activation and Overcomes Tumor Cell Programmed Death Ligand 1-Mediated Immune Suppression
Samuel T. Haile et al.
JOURNAL OF IMMUNOLOGY (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B)
Vincenzo Formica et al.
MEDICAL ONCOLOGY (2013)
Tumor-infiltrating PD1-Positive Lymphocytes and FoxP3-Positive Regulatory T Cells Predict Distant Metastatic Relapse and Survival of Clear Cell Renal Cell Carcinoma
Myoung Jae Kang et al.
TRANSLATIONAL ONCOLOGY (2013)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
Trial watch Chemotherapy with immunogenic cell death inducers
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2013)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway
Jiao Chen et al.
IMMUNOBIOLOGY (2012)
Cancer classification using the Immunoscore: a worldwide task force
Jerome Galon et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
CD73: a potent suppressor of antitumor immune responses
Paul. A. Beavis et al.
TRENDS IN IMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer
Marie Tosolini et al.
CANCER RESEARCH (2011)
Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms
Mikayel Mkrtichyan et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma
Bill G. Richendollar et al.
HUMAN PATHOLOGY (2011)
RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells
Lisa Borkner et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Clinical Development of the Anti-CTLA-4 Antibody Tremelimumab
Antoni Ribas
SEMINARS IN ONCOLOGY (2010)
Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
Paolo A. Ascierto et al.
SEMINARS IN ONCOLOGY (2010)
A dimeric structure of PD-L1: functional units or evolutionary relics?
Yong Chen et al.
PROTEIN & CELL (2010)
A systematic review of humoral immune responses against tumor antigens
Miriam Reuschenbach et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy
Melinda Morris et al.
CLINICAL CANCER RESEARCH (2008)
The anticancer immune response: indispensable for therapeutic success?
Laurence Zitvogel et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis
Ping Zhang et al.
MOLECULAR IMMUNOLOGY (2008)
Tumor antigen-specific T helper cells in cancer immunity and immunotherapy
KL Knutson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Immunosuppressive networks in the tumour environment and their therapeutic relevance
WP Zou
NATURE REVIEWS CANCER (2005)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Share Paper
